U.S. Markets closed

3 Health Care Stocks Rallying After US Midterms

CORAL GABLES, FL / ACCESSWIRE / November 7, 2018 / Healthcare stocks are rallying after Tuesday's US midterm elections. The Sector SPD Healthcare ETF (XLV) has climbed to highs of $92.24 as of 9:45AM EST. According to Modern Healthcare* the healthcare industry will continue to drive the nation's employment growth through 2026 by adding around 4 million new jobs, accounting for about a third of total job growth, according to Bureau of Labor Statistics data.

Modern Healthcare cites that ''the healthcare industry has long fueled the country's economy. Demand is expected to pick up as the population ages, people live longer, more gain insurance coverage and chronic conditions become more prevalent.''

With home health and other emerging interests gaining attention, stocks within the sector are beginning to see higher activity in the market. Companies in focus today include Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI), PDL BioPharma, Inc. (PDLI) and Ampio Pharmaceuticals, Inc. (AMPE)

Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) is focused on developing innovative approaches that combine human skill based expertise with emerging technologies for the healthcare industry. The company has recently seen market activity that is higher than average and could be attributed to the company's most recent announcements. Aside from obtaining DTC eligibility in the US to allow shares to be more easily and economically transferred between brokerage accounts electronically within the United States, Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) has been expanding its business footprint.

In October, Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) announced that it has selected Reliq Health Technologies Inc. as its exclusive technology partner. Reliq will be providing Premier's subsidiary, HealthVue, primary care clinics with a HealthVue-branded telemedicine, remote monitoring & AI solution for its clinical staff and more than 100,000 active patients.

In addition to this, Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) announced this week that as a part of its expansion plans it will enter the Pharmacy market via acquisition and/or launching a new Canada based pharmacy in H1-2019. With Premier's acquisition of HealthVue Medical Clinics in August, this could be the next phase of growth for the company.

Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) has already seen strong movement during the early morning session on Wednesday.

For More Information On Premier Health Group, Click Here

PDL BioPharma, Inc. (PDLI) reported its financial results for the three and nine months ended September 30, 2018 this week. Highlights included total revenues of nearly $68 million as well as the completion of a $25 million share repurchase program.

Our third quarter revenues increased 8% from the prior year to $68 million, reflecting higher product sales and $42 million in royalty rights revenue that included an increase in fair value of the royalty rights from Assertio Therapeutics, formerly known as Depomed, as a result of our purchase of the remaining interest in royalty payments of this asset," said John P. McLaughlin, CEO of PDL. "We benefitted from a particularly strong showing during the quarter from the type 2 diabetes drug Glumetza®, and I'm pleased to report that overall the Assertio asset has performed substantially better than we expected. With Tekturna®, we are cautiously optimistic about the transition to a non-personal promotion campaign from a direct sales model, which we completed mid-way through the third quarter. Tekturna sales remained stable throughout the quarter, with the new sales strategy reducing costs and increasing profitability."

Shares of PDL have climbed higher on Wednesday morning.

For More Information On PDL BioPharma, Click Here

Ampio Pharmaceuticals, Inc. (AMPE) provided an update of the regulatory and clinical path activities required to file a Biologics License Application (BLA) for Ampion™ for the treatment of severe osteoarthritis-of-the-knee (OAK).

According to Ampio, the primary objective of the Open-Label Extension (OLE) study, which followed the completion of the AP-003-C study, was to investigate the safety and tolerability of patients with severe osteoarthritis of the knee (KL4) receiving up to 5 injections of Ampion administered every 12 weeks, but efficacy was tracked and reported.

Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. Shares of the company saw highs of $0.709 on Wednesday morning.

For More Information On Ampio, Click Here

What Is Stock Price (StockPrice.com)?

Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.

StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.

At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 – 4/1/2018 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid ''500,000'' shares of restricted common shares. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six month restriction is complete on 4/1/2019 we plan to sell the ''500,000'' shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.

*Modern Healthcare: https://www.modernhealthcare.com/article/20171027/NEWS/171029879

Contact Information:

news@stockprice.com

SOURCE: StockPrice.com